Koselugo Phase III Trial Meets Primary Endpoint in Adults with Neurofibromatosis Type 1
核心洞察
AstraZeneca's Koselugo (selumetinib) demonstrated a statistically significant and clinically meaningful objective response rate versus placebo in adults with neurofibromatosis type 1 (搜索) (NF1).
The KOMET Phase III trial is the largest global, randomized, double-blind, placebo-controlled study in adults with NF1, showing a reduction in tumor volume.
The safety profile of Koselugo in the adult trial was consistent with previous trials in children and adolescents, with no new safety signals identified.
AstraZeneca's Koselugo (selumetinib) has shown positive results in the global KOMET Phase III trial, demonstrating a statistically significant and clinically meaningful objective response rate compared to placebo in adult patients with neurofibromatosis type 1 (搜索) (NF1). These findings suggest that Koselugo, already approved for certain children with NF1, could potentially benefit adult patients who currently have no approved targeted treatment options.
KOMET Trial Details and Results
The KOMET trial is the largest global, randomized, double-blind, placebo-controlled, multicenter Phase III trial conducted in adults with NF1. In this study, Koselugo, an oral selective MEK (搜索) inhibitor, met its primary endpoint by demonstrating a reduction in tumor volume. The results build upon the established safety and efficacy profile of Koselugo in children, supporting its potential expanded use in adult populations.
Safety Profile
The safety profile of Koselugo in the adult NF1 trial was consistent with that observed in previous clinical trials involving children and adolescents. No new safety signals were identified, reinforcing the drug's established safety profile.
Neurofibromatosis Type 1 (NF1)
NF1 is a rare, progressive genetic condition affecting an estimated 1.7 million individuals worldwide, the majority of whom are adults. In 30-50% of patients, tumors develop on the nerve sheaths, potentially causing debilitating symptoms such as disfigurement, dysfunction, and persistent pain. Currently, there are no approved treatments specifically for adults with NF1, leaving many to undergo multiple surgeries to manage the condition.
Implications and Future Steps
"These promising results demonstrate that Koselugo, the first and only approved targeted therapy for certain children with NF1 PN, now has the potential to benefit adult patients for whom there are no approved targeted therapies," said Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease. AstraZeneca plans to share the KOMET trial data with regulatory authorities and present the findings at an upcoming medical meeting. AstraZeneca and Merck & Co. (搜索), Inc. are jointly developing and commercializing Koselugo globally.